River Global Investors’s Impax Laboratories, Inc. IPXL Stock Holding History

River Global Investors’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-55,000	Closed	-$917K	–	130
2017 Q4	$917K	Hold	55,000	–	–	0.1%	110
2017 Q3	$1.11M	Hold	55,000	–	–	0.17%	99
2017 Q2	$884K	Sell	55,000 -8,000	-13%	-$118K	0.16%	95
2017 Q1	$795K	Buy	+63,000	New	+$761K	0.18%	99

Other funds holding IPXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TCW Group Los Angeles, California $13.3B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

River Global Investors's IPXL Position: Q1 2018 in Review

River Global Investors sold out of Impax Laboratories, Inc. (IPXL) in Q1 2018, closing a stake of 55,000 shares — an estimated $917K sold.

River Global Investors first reported a position in IPXL in Q1 2017 and held it in 4 quarters. The position peaked at $1.11M in Q3 2017. 188 funds tracked by Wall St. Rank hold IPXL as of Q1 2018.

River Global Investors reported no remaining Impax Laboratories, Inc. position as of Q1 2018 after selling out during the quarter.
River Global Investors sold 55,000 Impax Laboratories, Inc. shares in Q1 2018, an estimated $917K.
River Global Investors first reported a position in Impax Laboratories, Inc. in Q1 2017 and held it in 4 quarters.
River Global Investors's Impax Laboratories, Inc. position peaked at $1.11M in Q3 2017.
188 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2018.

Based on River Global Investors's 13F filing for Q1 2018, filed 11 May 2018.